Laudato si’ y la Agenda 2030, un llamado universal

Se analiza la vinculación de la encíclica Laudato Si, con los objetivos del desarrollo sustentable de los objetivos 2030.Fil: Di Paola, Maria Eugenia. Universidad de Buenos Aires. Facultad de Derecho; Argentina. Gobierno de la Ciudad Autonoma de Buenos Aires. Ministerio de Ambiente y Espacio Publico. Programa de Las Naciones Unidas Para El Desarrollo - P.n.u.d..; ArgentinaFil: Canziani, Pablo Osvaldo. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Unesco; ArgentinaFil: Ju, Yeon Kim. Organización de Las Naciones Unidas; Argentin

The shift from high to low turnover bone disease after parathyroidectomy is associated with the progression of vascular calcification in hemodialysis patients: A 12-month follow-up study

Parathyroidectomy (PTX) may cause low levels of PTH, leading to an excessive reduction of bone turnover, which is associated with poor outcomes in dialysis patients, including vascular calcification (VC). We aimed to prospectively investigate the impact of PTX on bone remodeling and its potential consequence on the progression of VC in hemodialysis patients. In this prospective study, 19 hemodialysis patients with severe secondary hyperparathyroidism (sHPT) were evaluated. All patients underwent laboratorial tests and coronary tomography at baseline and, 6 and 12 months after PTXbone biopsy was performed at baseline and 12-month. At baseline, all patients had increased PTH levels up to 2500 pg/mL and high turnover bone disease in their bone biopsies. Fourteen (74%) patients had VC. During the follow-up, there was a significant decrease of PTH at 6 and 12-month. At 12-month, 90% of the patients evolved to low turnover bone disease. During the period of the hungry bone syndrome (first 6 months), no change of coronary calcium score was observed. However, calcium score increased significantly thereafter (12(th) month). There was an association between VC progression and the severity of low turnover bone disease. In conclusion, the shift from high to low turnover bone disease after PTX occurs in parallel to VC progression, contributing to the understanding of the complex pathophysiology involving mineral metabolism and cardiovascular disease in hemodialysis patients.National Counsel of Technological and Scientific Development (CNPq)Univ Fed Sao Paulo, Nephrol Div, Sao Paulo, BrazilUniv Fed Parana, Nephrol Div, Curitiba, Parana, BrazilUniv Fed Sao Paulo, Head & Neck Surg Div, Sao Paulo, BrazilUniv Sao Paulo, Cardiol Div, Sao Paulo, BrazilUniv Fed Sao Paulo, Nephrol Div, Sao Paulo, BrazilWeb of Scienc

Apolipoprotein E polymorphism modulation of asymmetric dimethylarginine in hypertensive patients is determined by renal function

Background: Endothelial dysfunction is considered an early step of atherosclerotic vascular disease. Asymmetric dimethylarginine (ADMA), the main endogenous inhibitor of nitric oxide synthase (NOS), plays a critical role in the process of atherosclerosis in a uremic environment. Increased plasma ADMA not only works as a cardiovascular morbidity biomarker but it is also involved in the genesis of atherosclerosis in renal disease. Considering the relationships of apolipoprotein E(ApoE) polymorphism with LDL cholesterol (LDL-C) levels and coronary risk, it is possible that it brings on susceptibility to endothelial dysfunction and atherogenesis seen on uremia. Methods: Six hundred twenty patients were stratified according to glomerular filtration rate (GFR) estimated by Chronic Kidney Disease Epidemiology Collaboration (CKDEPI) formula: group I > 60 mL/min, group II 15 mL/min, and group III <= 15 mL/min or in hemodialysis. Polymorphic ApoE analysis was performed by polymerase chain reaction amplification (PCR). Plasma ADMA levels were measured by high performance liquid chromatography (HPLC). Groups were compared on clinical and laboratory characteristics as well as allele and genotype distribution towards. Results: The epsilon 2 allele of ApoE was present in 62 (10.3 %) patients, epsilon 3 allele in 581 (96.2 %), and epsilon 4 allele in 114 (18.9 %). Their distribution among the 3 groups was uniform. Such uniformity was not observed when we considered endothelial function measured by asymmetric dimethylarginine. In group III, the frequency of epsilon 4 allele was significantly lower in the third tertile compared with the first tertile (14.7 versus 53.3 %, P = 0.000; Pearson chisquare). In groups I and II, there was no difference in allele frequency according to ADMA levels. This association remained significant even after confouding factors corrections (OR 0.329, 95 % CI 0.155 - 0.699, P = 0.004). Conclusions: The results of this study shows that the frequency of epsilon 4 allele of ApoE is significantly lower among hypertensive patients on hemodialysis with the highest levels of ADMA. Uremia is capable of determining lower plasma ADMA levels in hypertensive epsilon 4 allele carriers.Fundo de Amparo a Pesquisa do Estado de Sao Paulo/FAPESPUniv Fed Sao Paulo, Nephrol Div, R Pedro de Toledo 781 14 Andar, BR-04039032 Sao Paulo, BrazilTufts Univ, New England Med Ctr, Nephrol Div, Boston, MA 02111 USAHosp Israelita Albert Einstein, Res & Educ Inst, Sao Paulo, SP, BrazilUniv Fed Sao Paulo, Nephrol Div, R Pedro de Toledo 781 14 Andar, BR-04039032 Sao Paulo, BrazilWeb of Scienc

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

Arritmias cardíacas em pacientes submetidos a dialise peritoneal ambulatorial continua

BV UNIFESP: Teses e dissertaçõe

Coronary artery calcification, systemic inflammation markers and mineral metabolism in a peritoneal dialysis population

Aims: To assess the prevalence of coronary artery calcification (CAC) in peritoneal dialysis (PD) patients and to determine whether comorbidities such as inflammation, dyslipidemia and mineral metabolism disorders correlate with its development. Methods: Forty-nine PD patients (45% male; median age, 52 years) were submitted to multislice computed tomography. Inflammatory markers, anti-oxidized LDL antibody, calcium-phosphate balance and lipid profiles were assessed. Results: Twenty-nine patients (59.2%) presented CAC (median calcium score, 234.7 Agatston units). Patients with CAC were older than those without, more frequently presented a history of coronary artery disease or hypertension and had lower HDL cholesterol levels, as well as presenting higher levels of osteoprotegerin and LDL oxidation. the logistic regression revealed that the independent determinants of CAC were age (odds ratio = 1.12; p = 0.006) and number of prescribed anti-hypertensive drugs (odds ratio = 2.38; p = 0.048). When the population was stratified by calcium score quartile, soluble Fas levels were significantly higher in patients with severe calcification. in patients younger than 45, CAC correlated positively with phosphorus levels (r = 0.52; p = 0.04). Conclusion: in PD patients, CAC is highly prevalent. Our results indicate that conditions such as inflammation and mineral disturbances are associated with its development. Copyright (c) 2006 S. Karger AG, Basel.Universidade Federal de São Paulo, Div Nephrol, São Paulo, BrazilUniversidade Federal de São Paulo, Div Nephrol, São Paulo, BrazilWeb of Scienc

A hipoalbuminemia parece estar associada a uma maior taxa de hospitalização nos pacientes em hemodiálise

Resumo Introdução: Anemia, inflamação e hipoalbuminemia são complicações frequentemente observadas em pacientes submetidos à hemodiálise crônica. Existem poucos dados nacionais que avaliam a associação dessas condições à morbidade e mortalidade especialmente considerando a região nordeste do país onde a ocorrência de anemia e desnutrição é elevada. Objetivo: O objetivo desse estudo foi avaliar o impacto da presença da anemia, inflamação e hipoalbuminemia sobre os desfechos clínicos (óbito e hospitalização) de pacientes sob hemodiálise. Método: Trata-se de um estudo de coorte prospectivo observacional com pacientes pre avaliados 221 pacientes adultos, considerando-se os valores de hemoglobina, proteína C reativa (PCR), albumina sérica no início do estudo. A ocorrência de hospitalização e óbito foi computada em um seguimento aproximado de 13 meses. Resultados: A ocorrência de hospitalização e óbito não diferiu entre os grupos com e sem anemia (Hb ≤ 10g/dL) ou inflamação (PCR ≥ 0,5mg/dL). Houve um maior número de hospitalização entre os pacientes com hipoalbuminemia. A albumina não apresentou correlação com os níveis séricos de PCR. Observou-se um menor tempo livre de hospitalização entre os pacientes com hipoalbuminemia (p = 0,008), houve uma tendência de menor tempo livre de hospitalização entre os pacientes com PCR aumentado (p = 0,08), e a anemia não se relacionou com o tempo livre de hospitalização. Não houve diferença na sobrevida em relação à presença de anemia, inflamação e hipoalbuminemia. A análise de regressão de Cox apontou a hipoalbuminemia como fator independente relacionado à hospitalização, mesmo após ajustes para idade, presença de diabetes, PCR e hemoglobina. Conclusão: A hipoalbuminemia, e não anemia ou inflamação, mostrou-se um marcador independente de hospitalização em pacientes submetidos à hemodiálise